As communicated on 3 August 2007 in connection with the release of
Novo Nordisk's financial results for the first six months of 2007,
Novo Nordisk's Board of Directors has approved a stock split of the
Novo Nordisk B shares listed on the OMX Nordic Exchange and the
London Stock Exchange as well as of the American Depositary Receipts
(ADRs) listed on the New York Stock Exchange (NYSE). The trading unit
of the Novo Nordisk B shares listed on the stock exchanges in
Copenhagen and London will be changed from DKK 2 to DKK 1. The ratio
of B shares to ADRs listed on the NYSE will remain 1:1. These changes
in trading units will take effect as of 3 December 2007 for the Novo
Nordisk B shares and as of 17 December for the ADRs.
Further details on the stock split
On 3 December 2007, the Novo Nordisk A/S B shares traded on the OMX
Nordic Exchange and on the London Stock Exchange will be split into
two shares. The last day of trading in the old shares will be 30
November 2007 and the first day of trading in the new shares will be
3 December 2007. The record date is 30 November 2007.
On 17 December 2007, each of Novo Nordisk's ADRs listed on the NYSE
will also be split. On 20 December, new ADRs will be distributed in
the proportion of one additional ADR per existing ADR to ADR holders
of record as of 30 November.
Hence, the ratio of B shares to ADRs listed on the NYSE will remain
1:1. The new shares issued due to the split will be of the same type
and class as the original shares.
Due to operational reasons, from 3 December through 16 December 2007,
the Novo Nordisk B shares listed on the stock exchanges in Copenhagen
and London will be traded post-split whereas the ADRs listed on the
NYSE will be traded pre-split. Post-split trading on the NYSE will
start on 17 December 2007.
JPMorgan, the depositary bank of Novo Nordisk's ADRs, will not
execute issuances and/or cancellations of ADRs between close of
business 29 November and close of business 19 December 2007. However,
the trading of Novo Nordisk's ADRs on the NYSE will continue as
normal.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. The company has the broadest diabetes product portfolio in the
industry, including the most advanced products within the area of
insulin delivery systems. In addition, Novo Nordisk has a leading
position within areas such as haemostasis management, growth hormone
therapy and hormone replacement therapy. Novo Nordisk manufactures
and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and
society. With headquarters in Denmark, Novo Nordisk employs
approximately 25,800 employees in 79 countries, and markets its
products in 179 countries. Novo Nordisk's B shares are listed on the
stock exchanges in Copenhagen and London. Its ADRs are listed on the
New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Mike Rulis Mads Veggerby Lausten
Tel (direct): (+45) 4442 3573 Tel (direct): (+45) 4443 7919
mike@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel (direct): (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel (direct): (+1) 609 514 8316 Tel (direct): (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 33 / 2007